Earnings ·
Clearmind Medicine Inc. filed its unaudited condensed interim consolidated financial statements for the three and nine…
CMNDClearmind Medicine Inc.
Clearmind Medicine Inc. filed its unaudited condensed interim consolidated financial statements for the three and nine months ended July 31, 2026. The company reported a net loss of $907,291 for the quarter and $6,809,527 for the nine-month period, with cash and cash equivalents increasing to $12,035,210 from $3,923,058 at the prior year-end. The filing details significant capital raising activities, including the conversion of $8,899,559 in convertible promissory notes into 1,778,626 common shares and proceeds of $7,245,761 from equity issuances. Additionally, the company recorded a gain on the revaluation of derivative warrant liabilities of $496,061 for the nine months ended July 31, 2026. Clearmind Medicine Inc. operates in the biopharmaceutical industry and is engaged in clinical-stage development of psychedelic-derived neuroplastogens for neuropsychiatric disorders.